Received Jun 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | — | — |
No additional AE; HCP called and reported a patient who received their first dose of MMR-II and VARIVAX on 08AUG2024 and was inadvertently given a second dose of MMR-II and VARIVAX on 15MAY2025. No additional information was known by reporter. No additional AE/PQC.; This spontaneous report was received from a medical assistant and refers to a 24-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 08-Aug-2024, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (lot # and expiration date were not reported) and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (indication, expiration date, and lot # were not reported) diluted with sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported) for prophylaxis. On 15-May-2025, the patient received inadvertently the second dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (lot # and expiration date were not reported) and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (indication, expiration date, and lot # were not reported) diluted with sterile diluent (MERCK STERILE DILUENT) (indication, expiration date, and lot # were not reported) (Inappropriate schedule of product administration). No additional adverse event was reported.
Sterile diluent